therapeutic allogeneic lymphocytes

PreclinicalCell therapy

therapeutic allogeneic lymphocytes is one of 73 biologic programs targeting Aplastic Anemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aplastic AnemiaActive, not recruiting

ImmunodeficiencyActive, not recruiting

Aplastic AnemiaPreclinical

Active, not recruiting

ImmunodeficiencyPreclinical

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Fuzeon

CConrado Roberto Hoffmann Filho

Approved

7 2

Adenocard

Rayos

1 4

Busulfex

Akero Therapeutics

Approved

1 5

Viramune

Boehringer Ingelheim

Approved

1 6

Cabenuva

GSK

Phase 3

4 7

Immunoglobulin

Sanofi

Phase 3

2 8

Cytosar

Teva

Phase 2

1 9

Vepesid

AAvyxa

Phase 2

1 10

Bicnu

MMelissa K Accordino

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stem Cell Transplant9 trials

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00096161·36 enrolled

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00060372·21 enrolled

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00248430·20 enrolled

Show 6 more trials

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Terminated·UUniversity of California, San Francisco·N/A·NCT00301860·8 enrolled

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00245037·147 enrolled

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005941

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·YYale University·Phase 1·NCT00104975·20 enrolled

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00448201·71 enrolled

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Completed·UUniversity of California, San Francisco·N/A·NCT00296023·25 enrolled

Kidney Cancer9 trials

Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

Withdrawn·FFox Chase Cancer Center·Phase 2·NCT00025519

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262886·35 enrolled

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Completed·UUNICANCER·Phase 2·NCT00056095·57 enrolled

Show 6 more trials

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005851·11 enrolled

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00005799·55 enrolled

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00004135·19 enrolled

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT00853125·10 enrolled

Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT00176501·3 enrolled

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00027573·36 enrolled

Acute Lymphoblastic Leukemia4 trials

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00107354

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00027547

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00052520·37 enrolled

Show 1 more trial

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Stem Cell Transplantation4 trials

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Completed·UUniversity of Maryland, Baltimore·Phase 1·NCT00005946

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00043979·60 enrolled

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00006350

Show 1 more trial

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00044954

Acute Myeloid Leukemia4 trials

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00053014·5 enrolled

Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia

Completed·UUniversity of Colorado, Denver·Phase 2·NCT00005801

Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission

Withdrawn·UUniversity of Southern California·Phase 2·NCT02587871

Show 1 more trial

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00274846·21 enrolled

25 more indications

Myeloid Leukemia3 trials

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 2·NCT00004878

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00052598·7 enrolled

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003145·18 enrolled

Breast Cancer3 trials

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Terminated·UUniversity of California, San Diego·Phase 2·NCT00074269·5 enrolled

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

Withdrawn·—·Phase 2·NCT00006261

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020176

Hematologic Malignancies3 trials

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01760655·62 enrolled

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01118013·6 enrolled

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 2·NCT01839916·77 enrolled

Chronic Myelogenous Leukemia2 trials

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00110058·40 enrolled

Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00002778·40 enrolled

Allogeneic Hematopoietic Cell Transplant2 trials

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00448357·54 enrolled

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053989·41 enrolled

Leukemia2 trials

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005802

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00066417·51 enrolled

Lymphoma2 trials

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00041288·10 enrolled

Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

Withdrawn·AAIDS Malignancy Consortium·Phase 2·NCT00024128

Lymphoproliferative Disease2 trials

Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation

Completed·UUniversity of Edinburgh·Phase 3·NCT00033475·50 enrolled

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 1·NCT00176475·2 enrolled

Chronic Lymphocytic Leukemia2 trials

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·N/A·NCT00003196·63 enrolled

Metastatic Melanoma1 trial

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00871481·10 enrolled

Allogeneic Stem Cell Transplantation1 trial

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00080925·20 enrolled

Ovarian Epithelial Cancer1 trial

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019136

Aplastic Anemia1 trial

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Unknown status·UUniversity of California, San Francisco·N/A·NCT00295997·35 enrolled

Hematopoietic Cell Transplant1 trial

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00068718·35 enrolled

Cytomegalovirus Infection1 trial

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00769613·20 enrolled

Hematologic Cancer1 trial

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00003243

Lymphoid Malignancies1 trial

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Completed·RRobert Lowsky·Phase 1·NCT01523223·16 enrolled

Bone Marrow Transplant1 trial

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Completed·—·Phase 1·NCT00569283·18 enrolled

Bone Marrow Transplantation1 trial

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003153·22 enrolled

Melanoma1 trial

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006233

Multiple Myeloma1 trial

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00003954·40 enrolled

Immunodeficiency1 trial

Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection

No longer available·FFred Hutchinson Cancer Center··NCT00547235

Bone Marrow Failure Syndrome1 trial

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Completed·UUniversity of California, San Francisco·Phase 1·NCT00295971·21 enrolled

Relapsed or Refractory1 trial

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Completed·UUniversity of Medicine and Dentistry of New Jersey·Phase 1·NCT00161187·37 enrolled

Anaplastic Astrocytoma1 trial

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Completed·CCity of Hope Medical Center·Phase 1·NCT01082926·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 67 trial records for therapeutic allogeneic lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — therapeutic allogeneic lymphocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for therapeutic allogeneic lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: EEastern Cooperative Oncology Group

therapeutic allogeneic lymphocytes

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stem Cell Transplant9 trials

Kidney Cancer9 trials

Acute Lymphoblastic Leukemia4 trials

Stem Cell Transplantation4 trials

Acute Myeloid Leukemia4 trials

Myeloid Leukemia3 trials

Breast Cancer3 trials

Hematologic Malignancies3 trials

Chronic Myelogenous Leukemia2 trials

Allogeneic Hematopoietic Cell Transplant2 trials

Leukemia2 trials

Lymphoma2 trials

Lymphoproliferative Disease2 trials

Chronic Lymphocytic Leukemia2 trials

Metastatic Melanoma1 trial

Allogeneic Stem Cell Transplantation1 trial

Ovarian Epithelial Cancer1 trial

Aplastic Anemia1 trial

Hematopoietic Cell Transplant1 trial

Cytomegalovirus Infection1 trial

Hematologic Cancer1 trial

Lymphoid Malignancies1 trial

Bone Marrow Transplant1 trial

Bone Marrow Transplantation1 trial

Melanoma1 trial

Multiple Myeloma1 trial

Immunodeficiency1 trial

Bone Marrow Failure Syndrome1 trial

Relapsed or Refractory1 trial

Anaplastic Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News